Barclays analyst Emily Field lowered the firm’s price target on Roche to CHF 230 from CHF 250 and keeps an Equal Weight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche reports Q1 group sales CHF 14.4B vs. CHF 15.3B last year
- Roche confirms outlook for 2024
- [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
- VGK vs. EZU: Which Is the Better European Stock ETF?
- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
